A recent article published in the Journal of Stomatology, Oral and Maxillofacial Surgery (Volume 120, Issue 2, April 2019, Pages 128-132) made a review with the title 3D Bioprinting: principles, fantasies and prospects. It is based on a PubMed/MEDLINE search that was performed with 40 publications.
What is this technique and what is bioink made of?
As we have said in different articles (see HERE) this technique opens an avenue for regenerative medicine and the possibility of obtaining organs for transplantation. But like any new biotechnological advance, it is necessary to know the current state of this technique and its possible ethical difficulties.
3D bioprinting technique with bio-ink containing living cells and biomaterials
3D bioprinting major advancement could also replace classical tissue engineering
The authors (french scientists of the field of reconstructive surgery) say later, “The three pillars of tissue engineering are cells, scaffold, and signals (growth factors). The success of in vitro tissue culture is judged on the self-synthesis of the matrix and the multiplication of cells. There has been a major advancement in tissue engineering techniques in the field of skin substitutes. Today, skin substitutes are obtained in vitro from the culture of keratinocytes, issued from a small skin biopsy. After 4 to 6 weeks of culture, the autologous epidermal sheets can be grafted. This has changed the management of severe extended burns [8]. Unfortunately, this type of in vitro substitute is not available for other tissues.”
Current limits to bioink composition and activity into 3D impressed organ scaffold
The study signaled 2 main difficulties,
- […the lack of a consensus because of the very high number of parameters. There are so many options in bioink composition (cells and biomaterials), printing conditions (printer type, temperature, oxygen rate, speed of deposition), and maturation procedure (signals and bioreactors) that defining a gold standard for each tissue is a very hard task.
- Vascularization of the printed tissues is another challenge. The overall outcome of engineered tissue implants
depends on the success of microvessel formation, maturation, and patterning [39]. To survive, a cell must be close to the source of nutrients (blood circulation)…”
3D bioprinting major advancement. New prospects
Future reconstructive procedure according to the study
The study describes an imaginary procedure to explain the future of this technique and affirms, “In this way, we could imagine 2-step management for patients waiting for a reconstructive procedure. In a first 1-day appointment, the patient would have multiple biopsies under local anesthesia and would have a reference imaging. The custom-made free flap could then be printed and disposed in a bioreactor. A few weeks later, once the flap is functional, the surgery to implant the free flap could be performed. In the same way, autologous organs could be printed, with no need to wait for a donor and no indication for immunosuppressive medication. It would also put an end to illegal trade in human organs. In the specific situation of face transplantation, this would be of a major benefit to resolve the identity issue by creating a graft similar to the original face.
3D bioprinting major advancement toward personalized treatments
Considering that the medical profession is aiming toward personalized treatments and that social and technological evolutions are responsible for a decrease in the number of organ donors due to the reduction in accidental deaths, 3D bioprinting might be a very promising solution. In a more distant but considered ineluctable future, years’-long outer space travel will be the theatre of complex surgery in confined environments where no available tissue or organ donors will be found. This is actually a priority for all space agencies, and programs are already targeting this challenge, such as the current Vascular Tissue Challenge launched by NASA.”
Regarding regulatory and socio-ethical issues, the study says “The emerging applications of bioprinting are ‘‘difficult to fit into current legislative pillars or categories. Moreover, one of the key challenges in regulating additive manufacturing is the acknowledgment of the fact that biological and non-biological materials are regulated in different ways.’’ The issue is being treated at the European Parliament.
Ethical concerns to be resolved
The study finishes its work with these considerations that also our Observatory support. “One of the main ethical concerns is that bioprinting ‘‘is a costly procedure that is available mostly to those who can afford such treatment. The high cost of the bio-printing manufacturing process and the required production capacity raise social and distributive justice questions and issues of fair or equal access given also the highly individualized character of the products’’. Moreover, bioprinting ‘‘might be (mis-)used to improve organs by adding functions or interbreeding human cells with those of animals to give the patient a competitive edge over other individuals” (enhancement). “These legal and socio-ethical challenges must be anticipated in order to get the best out of bioprinting.”